Background
Methods
Patient eligibility
Histological evaluation
EGFR mutation analysis
Follow-up
Results
Clinicopathologic and histologic features
Number of patients | |
---|---|
Gender | |
Male | 79 |
Female | 57 |
Age (years) | |
Range | 34-79 |
Median | 57.6 |
<65 | 95 |
≥65 | 41 |
Smoking status | |
Never | 103 |
Former or current | 33 |
Tumor size | |
≥3 cm | 89 |
<3 cm | 47 |
Adjuvant chemotherapy | |
Yes | 37 |
No | 99 |
Grade | |
Well | 57 |
Moderate or poor | 79 |
Surgical procedure | |
Lobectomy | 119 |
Bilobectomy | 17 |
Pleural involvement | |
Yes | 69 |
No | 67 |
Lymphatic and/or vessel invasion | |
Yes | 12 |
No | 124 |
Histological subtypes (IASLC/ATS/ERS) | |
Invasive adenocarcinoma | |
Lepidicpredominant | 21 |
Acinarpredominant | 39 |
Papillarypredominant | 38 |
Micropapillarypredominant | 22 |
Solid-predominant | 14 |
Variants of invasive adenocarcinoma | 2 |
Survival analyses
5-year DFS rate (%) |
P
| 5-year OS rate (%) |
P
| |
---|---|---|---|---|
Gender | 0.313 | 0.601 | ||
Male (n = 79) | 53.4 | 60.7 | ||
Female (n = 57) | 51.7 | 66.7 | ||
Age (years) | 0.643 | 0.475 | ||
<65 (n = 95) | 50.1 | 59.7 | ||
≥65 (n = 41) | 56.8 | 67.2 | ||
Smoking status | 0.541 | 0.312 | ||
Never (n = 103) | 56.5 | 70.6 | ||
Former or current (n = 33) | 46.5 | 54.5 | ||
Tumor size | 0.214 | 0.295 | ||
>3 cm (n = 89) | 46.7 | 59.7 | ||
≤3 cm (n = 43) | 54.2 | 66.2 | ||
Adjuvant chemotherapy | 0.213 | 0.713 | ||
Yes (n = 37) | 59.1 | 67.9 | ||
No (n = 99) | 49.0 | 60.3 | ||
Grade | 0.675 | 0.233 | ||
Well (n = 57) | 59.6 | 73.3 | ||
Moderate or poor (n = 79) | 50.1 | 55.4 | ||
Pleural involvement | 0.769 | 0.961 | ||
Yes (n = 69) | 49.0 | 60.4 | ||
No (n = 67) | 55.2 | 67.5 | ||
Lymphatic and/or vessel invasion | 0.045 | 0.112 | ||
Yes (n = 12) | 39.1 | 51.7 | ||
No (n = 124) | 54.3 | 68.1 | ||
Histological subtypes (IASLC/ATS/ERS) | ||||
Lepidicpredominant | 0.042 | 0.307 | ||
Yes (n = 21) | 75.2 | 80.8 | ||
No (n = 115) | 50.8 | 59.3 | ||
Acinarpredominant | 0.782 | 0.443 | ||
Yes (n = 39) | 55..5 | 67.8 | ||
No (n = 97) | 49.0 | 58.9 | ||
Papillary predominant | 0.401 | 0.405 | ||
Yes (n = 38) | 57.6 | 72.1 | ||
No (n = 98) | 47.1 | 57.2 | ||
Micropapillary predominant | 0.041 | 0.175 | ||
Yes (n = 22) | 28.4 | 43.5 | ||
No (n = 114) | 61.1. | 62.9 | ||
Solid predominant | 0.049 | 0.211 | ||
Yes (n = 14) | 36.7 | 45.9 | ||
No (n = 122) | 57.7 | 65.1 | ||
Variants of invasive adenocarcinoma | 0.315 | 0.306 | ||
Yes (n = 2) | 100 | 100 | ||
No (n = 134) | 51.3 | 60.5 |
DFS | OS | |||||
---|---|---|---|---|---|---|
HR | 95% CI |
P
| HR | 95% CI |
P
| |
Lepidic predominant (yes/no) | 0.756 | 0.723-1.012 | 0.101 | 0.876 | 0.597-1.986 | 0.742 |
Micropapillary predominant (yes/no) | 1.473 | 1.041-1.786 | 0.048 | 1.342 | 0.764-1.987 | 0.214 |
Solid predominant (yes/no) | 1.210 | 0.987-1.978 | 0.076 | 1.229 | 0.746-2.158 | 0.435 |
lymphatic and/or vessel invasion (yes/no) | 1.153 | 0.979-2.143 | 0.079 | 1.075 | 0.774-3.547 | 0.843 |
Correlation with EGFR mutation and clinicopathologic characteristics
EGFR mutation number (n = 39) | Wild-type number (n = 63) |
P
| |
---|---|---|---|
Lepidic predominant | 0.29 | ||
Yes | 8 (20.5%) | 8 (12.7%) | |
No | 31 (79.5%) | 55 (87.3%) | |
Acinar predominant | 0.27 | ||
Yes | 9 (23.1%) | 21 (33.3%) | |
No | 30 (76.9%) | 42 (66.7%) | |
Papillary predominant | 0.57 | ||
Yes | 8 (20.5%) | 16 (25.4%) | |
No | 31 (79.5%) | 47 (74.6%) | |
Micropapillary predominant | 0.0026 | ||
Yes | 12 (30.7%) | 5 (7.9%) | |
No | 27 (69.3%) | 58 (92.1%) | |
Solid predominant | 0.0508 | ||
Yes | 1 (2.6%) | 11 (17.5%) | |
No | 38 (97.4%) | 52 (82.5%) | |
Variants of invasive adenocarcinoma | 0.69 | ||
Yes | 0 (0.0%) | 2 (3.2%) | |
No | 39 (100%) | 61 (96.8%) |